AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector

AbbVie Inc  (NYSE: ABBV ) has decided to terminate  the CD33 collaboration program with Alector Inc  (NASDAQ: ALEC ), developing AL003 for Alzheimer’s disease as one of two programs under the co-development and option agreement. As previously disclosed, Alector was reviewing the next steps  for the AL003 program. In November last year, Alector presented Phase 1 AL003 data  at the annual Clinical ... Full story available on Benzinga.com